Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

(e)

2018 Salary Increases and Bonus Plan for Named Executive Officers

On January17, 2018, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Intersect ENT, Inc. (the “Company”) approved annual salaries and target bonus percentages for 2018 for the Company’s Chief Executive Officer, Chief Financial Officer, Chief People Officer, Chief Operating Officer and General Counsel, each a “Named Executive Officer” (as defined under applicable securities laws). The 2018 compensation information for such executive officers is set forth on Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 5.02 Financial Statements and Exhibits

Exhibit

No.

Description

10.1 2018 Named Executive Officer Compensation.


Intersect ENT, Inc. Exhibit
EX-10.1 2 d514757dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 2018 Named Executive Officer Compensation   Name    Base Salary(Annual Rate) (1)      Target PerformanceBonus(% of Base Salary) (2)   Lisa D. EarnhardtPresident and ChiefExecutive Officer    $ 556,…
To view the full exhibit click here

About Intersect ENT, Inc. (NASDAQ:XENT)

Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.

An ad to help with our costs